These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34944713)

  • 1. Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays.
    Song J; Sokoll LJ; Chan DW; Zhang Z
    Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
    Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
    Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
    J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
    Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
    BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
    Chan A; Prassas I; Dimitromanolakis A; Brand RE; Serra S; Diamandis EP; Blasutig IM
    Clin Cancer Res; 2014 Nov; 20(22):5787-95. PubMed ID: 25239611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
    Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
    Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
    Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
    Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of serum parameters panels for the early detection of pancreatic cancer.
    Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
    Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum biomarker panels for the detection of pancreatic cancer.
    Brand RE; Nolen BM; Zeh HJ; Allen PJ; Eloubeidi MA; Goldberg M; Elton E; Arnoletti JP; Christein JD; Vickers SM; Langmead CJ; Landsittel DP; Whitcomb DC; Grizzle WE; Lokshin AE
    Clin Cancer Res; 2011 Feb; 17(4):805-16. PubMed ID: 21325298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
    Kruger D; Yako YY; Devar J; Lahoud N; Smith M
    PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA.
    Wu H; Guo S; Liu X; Li Y; Su Z; He Q; Liu X; Zhang Z; Yu L; Shi X; Gao S; Wang H; Pan Y; Ma C; Liu R; Dai M; Jin G; Liang Z
    BMC Med; 2022 Nov; 20(1):458. PubMed ID: 36434648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
    Vila-Navarro E; Duran-Sanchon S; Vila-Casadesús M; Moreira L; Ginès À; Cuatrecasas M; Lozano JJ; Bujanda L; Castells A; Gironella M
    Clin Transl Gastroenterol; 2019 Apr; 10(4):e00029. PubMed ID: 31009404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
    Hogendorf P; Durczyński A; Skulimowski A; Kumor A; Poznańska G; Strzelczyk J
    Cancer Biomark; 2018 Feb; 21(3):505-511. PubMed ID: 29171983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9.
    Majumder S; Taylor WR; Foote PH; Berger CK; Wu CW; Mahoney DW; Bamlet WR; Burger KN; Postier N; de la Fuente J; Doering KA; Lidgard GP; Allawi HT; Petersen GM; Chari ST; Ahlquist DA; Kisiel JB
    Clin Cancer Res; 2021 May; 27(9):2523-2532. PubMed ID: 33593879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Fit-For-Purpose Multi-Marker Panel for Early Diagnosis of Pancreatic Ductal Adenocarcinoma.
    Kim H; Huh S; Park J; Han Y; Ahn KG; Noh Y; Lee SJ; Chu H; Kim SS; Jung HS; Yun WG; Cho YJ; Kwon W; Jang JY; Kang UB
    Mol Cell Proteomics; 2024 Sep; 23(9):100824. PubMed ID: 39097268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Verification of the effectiveness of fucosylated haptoglobin as a pancreatic cancer marker in clinical diagnosis.
    Kuwatani M; Kawakami H; Kubota Y; Kawakubo K; Ito YM; Togo S; Ikeda T; Kusama K; Kobayashi Y; Murata T; Sakamoto N
    Pancreatology; 2019 Jun; 19(4):569-577. PubMed ID: 31031206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
    Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
    Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancreatitis.
    Mahajan UM; Oehrle B; Sirtl S; Alnatsha A; Goni E; Regel I; Beyer G; Vornhülz M; Vielhauer J; Chromik A; Bahra M; Klein F; Uhl W; Fahlbusch T; Distler M; Weitz J; Grützmann R; Pilarsky C; Weiss FU; Adam MG; Neoptolemos JP; Kalthoff H; Rad R; Christiansen N; Bethan B; Kamlage B; Lerch MM; Mayerle J
    Gastroenterology; 2022 Nov; 163(5):1407-1422. PubMed ID: 35870514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Rigorous Multi-Laboratory Study of Known PDAC Biomarkers Identifies Increased Sensitivity and Specificity Over CA19-9 Alone.
    Haab B; Qian L; Staal B; Jain M; Fahrmann J; Worthington C; Prosser D; Velokokhatnaya L; Lopez C; Tang R; Hurd MW; Natarajan G; Kumar S; Smith L; Hanash S; Batra SK; Maitra A; Lokshin A; Huang Y; Brand RE
    bioRxiv; 2024 May; ():. PubMed ID: 38826212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of urinary C-reactive protein as an early detection biomarker for pancreatic ductal adenocarcinoma.
    Ali N; Debernardi S; Kurotova E; Tajbakhsh J; Gupta NK; Pandol SJ; Wilson P; Pereira SP; Greenhalf B; Blyuss O; Crnogorac-Jurcevic T
    Front Oncol; 2024; 14():1450326. PubMed ID: 39309742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.